Department of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Shanghai Tangqiao Community Healthcare Center, Shanghai, China.
Cancer Med. 2022 Jan;11(2):348-357. doi: 10.1002/cam4.4450. Epub 2021 Dec 1.
The aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), and to investigate the better treatment to control MPE.
Malignant pleural effusion patients were enrolled in the study and treated with NCPC or IPHC under video-assisted thoracoscopic surgery (VATS). The chest drainage duration, clinical characteristics, and recurrence time of pleural effusion of patients were collected for statistical analysis. The chi-squared test and the Fisher's exact test were applied to compare the distribution differences in categorical variables. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and was compared by the log-rank test. The survival analysis was performed using the Cox proportional hazards method.
A total of 37 MPE patients were enrolled in this study. Twenty-seven patients received NCPC and 10 patients received IPHC under VATS. Significant differences were found in pathological types (p = 0.011), chest drainage duration (p = 0.005), and remission rate (p = 0.009) between two different treatment groups. The chest drainage duration of IPHC under VATS was shorter than the NCPC group (t = 2.969, p = 0.005). The remission rate of MPE in IPHC group was better than the NCPC one (OR = 0.031, 95% CI: 0.002-0.507, p = 0.015). The result of the Kaplan-Meier method showed that IPHC group could significantly prolong the PFS of patients with MPE compared to NCPC group (log-rank p = 0.002). Univariate cox regression analysis showed that patients with MPE in the IPHC group presented significant longer PFS than the NCPC group (HR = 0.264, 95% CI: 0.098-0.713, p = 0.009). Multivariate cox regression analysis further verified this conclusion (HR = 0.268, 95% CI: 0.096-0.753, p = 0.012).
Compared to the NCPC, the IPHC under VATS presents a better control effect on MPE, shorter tube placement time, and longer complete remission time. For this reason, we recommend IPHC under VATS as the first-line treatment for patients with MPE those who can tolerate minimally invasive surgery.
本研究旨在评估与常规胸腔热化疗(NCPC)相比,电视辅助胸腔镜手术(VATS)下的胸腔内热化疗(IPHC)治疗恶性胸腔积液(MPE)的疗效和安全性,并探讨更好的治疗方法来控制 MPE。
将 MPE 患者纳入研究,并在 VATS 下接受 NCPC 或 IPHC 治疗。收集患者的胸腔引流持续时间、临床特征和胸腔积液复发时间进行统计分析。采用卡方检验和 Fisher 确切概率法比较分类变量的分布差异。采用 Kaplan-Meier 法估计无进展生存期(PFS),并采用对数秩检验进行比较。采用 Cox 比例风险模型进行生存分析。
本研究共纳入 37 例 MPE 患者。27 例患者接受 NCPC 治疗,10 例患者接受 VATS 下的 IPHC 治疗。两组患者在病理类型(p=0.011)、胸腔引流持续时间(p=0.005)和缓解率(p=0.009)方面存在显著差异。VATS 下 IPHC 的胸腔引流持续时间明显短于 NCPC 组(t=2.969,p=0.005)。IPHC 组 MPE 的缓解率优于 NCPC 组(OR=0.031,95%CI:0.002-0.507,p=0.015)。Kaplan-Meier 法的结果表明,与 NCPC 组相比,IPHC 组可显著延长 MPE 患者的 PFS(log-rank p=0.002)。单因素 Cox 回归分析显示,IPHC 组 MPE 患者的 PFS明显长于 NCPC 组(HR=0.264,95%CI:0.098-0.713,p=0.009)。多因素 Cox 回归分析进一步验证了这一结论(HR=0.268,95%CI:0.096-0.753,p=0.012)。
与 NCPC 相比,VATS 下的 IPHC 对 MPE 具有更好的控制效果,胸腔引流管放置时间更短,完全缓解时间更长。因此,对于能够耐受微创手术的 MPE 患者,我们建议将 VATS 下的 IPHC 作为首选治疗方法。